Claim

In medical-record data, levetiracetam use was linked to longer survival for patients with diffuse midline gliomas but not for patients with hemispheric high-grade gliomas.

Type COMPARATIVE · truth-evaluable: yes · status at snapshot: ACTIVE · created seq 13498 · qualifiers {"population":"Medical-record association in patients; the accompanying growth result was from mice, not a clinical trial."}

a conjunction joins clauses that may be separately evaluable

Referenced 134 times: checked 2, looked up by assistants 0, viewed 86, shared 46. A count of attention, not evidence.

Topics

Medicine · 1efd24fe Health · 1efd24fe

Assessment

Supported

Score: 0.9781 under ledger-default@0.3.0 at snapshot 27745

3 of 4 review checks done · 1 counted · 2 by the author only

2 independent evidence lineages · review checks 1 of 4 · stability HIGH

Main unresolved issue: 4 counted evidence items have no independence review; repeats of one origin may be counted as several coverage:250d20d0-ff02-8715-9494-aa3befe833a9

Not yet independently audited.Evidence reviewed so far supports this claim, but only 1 of 4 review checks has been done.A quoted passage from med.stanford.edu was not found on the page when Galedra fetched it.

Why?

Strongest counted support: Stanford reports tumor-growth slowing in diffuse midline glioma mice and a survival association limited to diffuse midline glioma patients. weight 2.000000 evidence

Suppressed as dependent: The passage directly states longer survival association in diffuse midline glioma patients but not hemispheric high-grade glioma patients.

Review gaps: qualifiers reviewed, opposing search done, independence reviewed

What would most change this: One independent, direct measurement that contradicts this claim would move it from Supported to Supported.

Hide calculation

0.9781 under ledger-default@0.3.0 at snapshot 27745 · state Supported · Review checks: 1 of 4 · stability HIGH · 4 sources, 2 independent lineages

Model ledger-default@0.3.0 (the default model, not the answer) · snapshot 27745 · trace sha256:ae0e05b71fab89ac124da8d1fd25f5a4b4842e8a3e92e1899a5770aee42a64db

Last changed at entry seq 13916; nothing logged since has borne on this claim.

How the number was reached

Each counted link is weighed by multiplying the factors the model declares; a factor it does not declare is not shown. Every factor name below links to what that number means.

Link	Working	Weight	Counted as
6497f2ce support	relevance DIRECT 2.0 × observation DIRECT_TEXT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	1.800000	0.000000 (dependent strongest only, kept f3048afe)
f3048afe support	relevance DIRECT 2.0 × observation MEASUREMENT 1.0 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	2.000000	2.000000
b5cfa09b support	relevance DIRECT 2.0 × observation DIRECT_TEXT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	1.800000	1.800000
99a2bf03 qualify	relevance DIRECT 2.0 × observation EXPERT_ANALYSIS 0.3 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1	0.600000	0.000000 (non directional)

prior 0.50 → log-odds 0.000000 + 3.800000 (the counted weights) = 3.800000 → probability 0.9781

Under neighbouring settings of the same model: 0.9346 to 0.9929, a spread of 0.0583.

Half-even rounding, six places for weights and four for the probability. The same inputs under the same model reproduce this exactly; that is what the trace hash above is for. How a score is worked out explains every factor, why it is there, and what the model sets it to.

Your view

Registered views

Nobody has registered a view yet.

Registered views are personal belief, not evidence: they never change Galedra's assessment. Affiliations are self-declared and shown only for groups of 5 or more.

Checked as part of

Statements this claim was broken out of. The claim is scored on its own; a statement's reading only counts its claims.

“In medical-record data, levetiracetam use was linked to longer survival for patients with diffuse midline gliomas but not for patients with hemispheric...” · 1 claim · 28 September 2026
“Stanford researchers reported that levetiracetam slowed diffuse midline glioma growth in mice and was linked to longer survival in patients with diffuse...” · 2 claims · 28 September 2026

Evidence for

Stanford reports tumor-growth slowing in diffuse midline glioma mice and a survival association limited to diffuse midline glioma patients.

From Anti-seizure drug fights aggressive childhood brain tumors, Stanford Medicine-led study shows Read 2026-09-28 Relevance DIRECT Steps 0 Counted

The passage directly contrasts survival associations by tumor type and location.
The retrospective analysis found longer median survival associated with levetiracetam in DMG, but no survival effect in hemispheric pediatric high-grade glioma.

From Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma Read 2026-09-28 Relevance DIRECT Steps 0 Counted

Peer-reviewed primary data directly support the tumor-subtype contrast; the study itself cautions that prospective trials are needed.
The passage directly states longer survival association in diffuse midline glioma patients but not hemispheric high-grade glioma patients.

From Anti-seizure drug fights aggressive childhood brain tumors, Stanford Medicine-led study shows Read 2026-09-28 Relevance DIRECT Steps 0 Counted

Evidence against

None.

Qualifications

The authors caution that the survival association comes from small retrospective data and needs prospective studies before treatment conclusions.

From Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma Read 2026-09-28 Relevance DIRECT Steps 0 Counted

The claim correctly says “linked,” but the evidence is retrospective with small numbers and does not establish a causal treatment effect.

Suppressed as dependent

Evidence	Group	Kept instead
3f726eb2		f3048afe

Inferences

Concluded from

None.

Used as a premise in

None.

An inference is interpretation, not evidence: it never changes the assessment of its conclusion. Each premise is a claim with its own evidence.

Threads

None. Threads are for disagreements about how a determination was made — a statement whose figures are not in the passage it rests on, two sources that may share an origin. Something about the world belongs in the evidence above.

Claim edges

None. Edges are stored and displayed; v0.1 does not propagate probability across them.

Review checklist

Review checks: 1 of 4

3 checks by this claim's own author, alongside the independent review above. 1 OPPOSING EVIDENCE SEARCH · 1 QUALIFIER CHECK · 1 EVIDENCE VERIFICATION. A check by the person who recorded a claim does not raise its review coverage.

Check	Done	By
qualifiers reviewed	no
opposing search done	no
independence reviewed	no
primary source reviewed	yes	6497f2ce, f3048afe, b5cfa09b, 99a2bf03

Summary

Supported. The main support is: Stanford reports tumor-growth slowing in diffuse midline glioma mice and a survival association limited to diffuse midline glioma patients. 83400e07

1 further item repeats the same origin and is not independent evidence. 3f726eb2

Qualifier: The authors caution that the survival association comes from small retrospective data and needs prospective studies before treatment conclusions. 91ea1158

A search for evidence in the opposing direction found none. 64fa42bd

Review checks: 1 of 4. coverage:250d20d0-ff02-8715-9494-aa3befe833a9

Generated by stub-v0.1; every sentence cites graph ids.

Contribution history

seq	event	detail
13498	APPENDED
13499	ACCEPT	AUTOMATIC_AFTER_VALIDATION
13506	LINK_EVIDENCE	by 1efd24fe (accepted)
13530	LINK_EVIDENCE	by 1efd24fe (accepted)
13536	TASK_RESULT	by 1efd24fe (accepted)
13538	TASK_RESULT	by 1efd24fe (accepted)

Score trace

{
  "claim": "250d20d0-ff02-8715-9494-aa3befe833a9",
  "links": [
    {
      "kept": "8e4e015e-ae58-87fb-bbda-4bedf3048afe",
      "link": "1d3732a1-f112-8e6a-a0fc-c3446497f2ce",
      "group": null,
      "reason": "dependent_strongest_only",
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "1d6a22e4-4360-80be-b225-8fcd3f726eb2",
      "direction": "SUPPORT",
      "magnitude": "1.800000",
      "relevance": "DIRECT",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "DIRECT_TEXT",
      "source_type": "PRIMARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "0.000000",
      "interpretive_steps": 0
    },
    {
      "link": "8e4e015e-ae58-87fb-bbda-4bedf3048afe",
      "group": null,
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "739fae63-4205-80e6-8192-b16183400e07",
      "direction": "SUPPORT",
      "magnitude": "2.000000",
      "relevance": "DIRECT",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "MEASUREMENT",
      "source_type": "PRIMARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "2.000000",
      "interpretive_steps": 0
    },
    {
      "link": "978f8fb5-b336-899f-abdf-91d2b5cfa09b",
      "group": null,
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "70c07162-5d08-8ab4-ae85-afc28767191e",
      "direction": "SUPPORT",
      "magnitude": "1.800000",
      "relevance": "DIRECT",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "DIRECT_TEXT",
      "source_type": "PRIMARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "1.800000",
      "interpretive_steps": 0
    },
    {
      "link": "fbc6f2b4-4a51-8610-a646-37ef99a2bf03",
      "group": null,
      "reason": "non_directional",
      "edition": "NAMED_OR_UNRELATED",
      "evidence": "e9bf293e-c0f8-84a4-ad38-cf4d91ea1158",
      "direction": "QUALIFY",
      "magnitude": "0.600000",
      "relevance": "DIRECT",
      "extraction": "UNVERIFIED",
      "provenance": "INDEPENDENT",
      "observation": "EXPERT_ANALYSIS",
      "source_type": "PRIMARY_TEXT",
      "authenticity": "UNVERIFIED",
      "audit_confirmed": false,
      "effective_weight": "0.000000",
      "interpretive_steps": 0
    }
  ],
  "model": "ledger-default@0.3.0",
  "prior": "0.50",
  "variants": {
    "spread": "0.0583",
    "permissive": "0.9929",
    "conservative": "0.9346"
  },
  "code_hash": "sha256:c61a6fdf35a754a0d7e958df149036a083c0eaeb7d2d2e52704ec32b0c36def7",
  "contested": false,
  "stability": "HIGH",
  "claim_type": "COMPARATIVE",
  "config_hash": "sha256:86768038080b8ab5233f1e4b7aba10af05b5bb44caa432095150b90e81209809",
  "probability": "0.9781",
  "provisional": true,
  "evidence_sum": "3.800000",
  "snapshot_seq": 13916,
  "prior_log_odds": "0.000000",
  "support_groups": 2,
  "model_dependent": false,
  "review_coverage": "0.25",
  "truth_evaluable": true,
  "assessment_state": "SUPPORTED",
  "review_checklist": {
    "qualifiers_reviewed": {
      "by": [],
      "ok": false
    },
    "opposing_search_done": {
      "by": [],
      "ok": false
    },
    "independence_reviewed": {
      "by": [],
      "ok": false
    },
    "primary_source_reviewed": {
      "by": [
        "1d3732a1-f112-8e6a-a0fc-c3446497f2ce",
        "8e4e015e-ae58-87fb-bbda-4bedf3048afe",
        "978f8fb5-b336-899f-abdf-91d2b5cfa09b",
        "fbc6f2b4-4a51-8610-a646-37ef99a2bf03"
      ],
      "ok": true
    }
  },
  "contradict_groups": 0,
  "rounding_boundary": false,
  "posterior_log_odds": "3.800000",
  "not_applicable_reason": null,
  "independence_unreviewed": 4
}